Virtu Financial LLC Takes Position in Bio-Rad Laboratories, Inc. $BIO

Virtu Financial LLC acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,218 shares of the medical research company’s stock, valued at approximately $672,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of BIO. Danske Bank A S bought a new position in Bio-Rad Laboratories during the 4th quarter worth approximately $30,000. Geneos Wealth Management Inc. lifted its position in Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Bio-Rad Laboratories in the fourth quarter valued at approximately $47,000. Farther Finance Advisors LLC boosted its stake in shares of Bio-Rad Laboratories by 76.9% during the fourth quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 80 shares during the period. Finally, Itau Unibanco Holding S.A. grew its holdings in shares of Bio-Rad Laboratories by 57.6% in the fourth quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company’s stock worth $60,000 after purchasing an additional 72 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $280.92 on Tuesday. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12. The firm’s fifty day simple moving average is $284.62 and its 200 day simple moving average is $289.24. The stock has a market cap of $7.52 billion, a P/E ratio of 46.28 and a beta of 1.08. Bio-Rad Laboratories, Inc. has a twelve month low of $228.40 and a twelve month high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The company had revenue of $592.10 million during the quarter, compared to the consensus estimate of $589.91 million. During the same quarter last year, the company posted $2.54 earnings per share. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. As a group, research analysts predict that Bio-Rad Laboratories, Inc. will post 9.42 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on BIO shares. Royal Bank Of Canada initiated coverage on shares of Bio-Rad Laboratories in a research note on Friday, May 15th. They issued an “outperform” rating and a $320.00 target price on the stock. Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price target for the stock from $375.00 to $300.00 in a report on Tuesday, April 7th. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings downgraded shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $303.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.